Drug Profile
Rifamexil
Alternative Names: MDL 62769Latest Information Update: 03 Aug 1998
Price :
$50
*
At a glance
- Originator Aventis
- Class Antibacterials; Rifamycins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycobacterium avium complex infections
Most Recent Events
- 03 Aug 1998 No-Development-Reported for Mycobacterium avium complex infections in USA (Unknown route)
- 29 Jan 1997 Two in vitro studies have been added to the pharmacodynamic and antimicrobial activity sections
- 27 Jan 1995 Preclinical development for Mycobacterium avium complex infections in USA (Unknown route)